EndoQuest Robotics Takes a Step into Advanced Robotic Surgery with NVIDIA

Houston, TX, October 30, 2025 – EndoQuest Robotics, Inc., a pioneer leader in endoluminal robotic surgical technology, announced that it will integrate the NVIDIA IGX Thor platform. This development is seen as a significant step towards the commercialization of EndoQuest's next-generation robotic system.

The collaboration will focus on integrating EndoQuest's visualization systems, robotic control, and secure cloud services with NVIDIA's accelerated computing and software stack. This will include technologies such as NVIDIA Holoscan, NVIDIA CUDA, and NVIDIA AI Enterprise, providing an architecture that combines real-time image processing, robotic control, and cloud-supported intelligence.

Eduardo Fonseca, CEO of EndoQuest Robotics, stated, "By harnessing NVIDIA's leading technology in the industry to enhance our visualization, control, and secure cloud services, we aim to optimize our system architecture for performance, reliability, and clinical scalability." He added, "This unified architecture is critical for advancing our technology in endoluminal robotics and achieving commercialization."

As part of this initiative, EndoQuest will leverage NVIDIA technologies for low-latency sensor processing and 3D visualization, precise and time-synchronized motion control, and secure cloud connectivity. These capabilities will support fleet management, data services, and artificial intelligence deployment. Findings from this collaboration will guide EndoQuest's product development and commercialization strategy for future robotic systems.

This effort aligns with EndoQuest's PARADIGM Trial, a multicenter critical study assessing the use of the endoluminal surgical (ELS) system in lower gastrointestinal (GI) tract procedures by colorectal surgeons and gastroenterologists.

EndoQuest Robotics, as a leading innovator in developing transformative endoluminal robotic technologies, aims to address unmet needs in gastrointestinal (GI) medicine. The company's patented technology allows procedures to be performed through natural orifices, aiming to provide a minimally invasive surgical approach with no visible scarring. Since its inception, EndoQuest has sought to improve patient outcomes and redefine minimal invasive surgical standards by collaborating with healthcare providers, researchers, and industry partners to develop its groundbreaking flexible robotic system.

EndoQuest's Endoluminal Surgical System is an investigational device, FDA approved, and has not yet been commercially available in the United States.